General Atlantic, a leading global growth equity firm, announced today that Justin Sunshine has joined the firm as a Managing Director in its New York office. Mr. Sunshine, who spent the past ten years at Blackstone, will focus on investments in the Healthcare sector.
Sanfer, one of Mexico’s leading independent pharmaceutical companies, today announced it has obtained a USD $500 million minority investment from Caisse de dépôt et placement du Québec (CDPQ), a long-term institutional investor. The investment, one of the largest minority private equity transactions in Mexico, will enable Sanfer to execute on its continued expansion plans across Mexico and the broader Latin American region.
Motif Ingredients Rebrands to Motif FoodWorks, Raises $27.5 Million to Fuel Animal-Free Ingredients R&D
Ingredients innovation company, Motif Ingredients, today announced it received $27.5 million in funding led by General Atlantic, a leading global growth equity firm, with participation from CPT Capital. The company also revealed a new brand identity and name, Motif FoodWorks, and announced a number of additions to its leadership team. The capital raise, evolution of its brand and expanded team strategically position Motif FoodWorks to fulfill its aspiration to extend the realm of what’s possible with animal-free ingredients.
PathAI Secures $60M in Series B Funding Led by General Atlantic and Existing Investor General Catalyst
PathAI, a global provider of artificial intelligence-powered technology for pathology, announced today that it has raised $60 million in Series B funding. The round was led by new investor General Atlantic, a leading global growth equity firm, with strong participation from General Catalyst and other existing investors. The new capital will fuel PathAI’s continued expansion as the company seeks to advance the medical discipline of pathology. General Atlantic Managing Director Dr. Michelle Dipp will be joining PathAI’s board of directors as the company advances its mission of offering faster, safer, and more powerful solutions for the diagnosis and sub-typing of diseases like cancer.
Rubicon Research Pvt Ltd (“Rubicon”), a global leader in innovative pharmaceutical product development, announced today that General Atlantic has become a significant shareholder in the company. General Atlantic, a leading global growth equity firm, is committing up to $100 million of primary capital and has acquired the stake held by Rubicon’s existing private equity shareholders. All other existing shareholders continue to maintain their shareholding in the company.
General Atlantic, a leading global growth equity firm, announced today that Rob Perez, former President and CEO of Cubist Pharmaceuticals, Inc. has joined the firm as an Operating Partner. Based in the firm’s New York office, Mr. Perez will have a particular focus on the biopharma and life sciences sectors, using his expertise to identify new investment opportunities and support the growth of the firm’s existing investments. Mr. Perez will be a part of the General Atlantic’s Resources Group, providing strategic counsel to the firm’s investment teams and portfolio companies.
Today, Health and Human Services Deputy Secretary Eric Hargan announced the initial core participants of the Deputy Secretary’s Innovation and Investment Summit (DSIIS) and December 18, 2018 as the date of the first meeting. As announced on September 19, 2018, the DSIIS will be a yearlong collaboration between healthcare innovation and investment professionals and HHS personnel who will meet quarterly to discuss the innovation and investment landscape within the healthcare sector, emerging opportunities, and the government’s role in facilitating more investment and accelerated innovation.
Hong Kong Asia Medical Holding Limited (“Asia Medical”) today announced a strategic partnership with a $150 million investment from General Atlantic, a leading global growth equity firm. Asia Medical is a leading privately-owned Chinese healthcare services provider and hospital operator specializing in heart surgery and cardiology, which operates under the brand name ‘Asia Heart’. The strategic partnership marks the expansion of General Atlantic’s investment focus into the healthcare and biotechnology sector in China.
Three leading oncology practices unite with partners in technology and finance to announce the launch of OneOncology, a patient-centric, physician-driven, and technology-powered company with a mission to improve the lives of everyone living with cancer.
Krishna Institute of Medical Sciences (KIMS Hospitals), a leading multi-disciplinary provider of healthcare services in Andhra Pradesh and Telangana, announced today that it has received a strategic growth investment from General Atlantic, a leading global growth equity firm. As part of the transaction, General Atlantic invested over USD 130 million, in a combination of primary capital and secondary purchases, to acquire a significant minority stake in the company.
Landmark Health (“Landmark” or the “Company”), a leading provider of in-home, risk-based medical care, is pleased to announce that General Atlantic, a leading global growth equity firm, has made a strategic investment in the Company.
Ginkgo Bioworks, the organism company, today announced the opening of Bioworks3–Ginkgo’s third foundry for prototyping and scaling engineered organisms. This expansion is supported by $275 million in a Series D round with participation from all previous investors, including Viking Global, Y Combinator’s Continuity Fund, and Cascade Investment, the private investment vehicle of William H. Gates III, as well as new investors, including General Atlantic, a leading global growth equity firm. This brings the company’s total funding to $429 million. The new foundry will bring the power of biology to new markets including pharmaceuticals, agriculture and textiles, and accelerate the timeline for bringing current projects to commercial scale.